FDA furlough threat
Executive Summary
FDAers and other HHS employees have been told to show up for work on Oct. 9 although the threat of furloughs has been revived by the House of Representative's 254 to 179 vote against the budget summit agreement on Oct. 5. On the same day, the government's stopgap omnibus spending bill expired and President Bush said he would not sign another temporary funding bill unless a budget resolution is passed. HHS made preparations to furlough FDAers for about seven days a month in case the Gramm-Rudman law goes into effect, but the agency said it would not do so during the first two weeks of October.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.